KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Non-Current Deferred Tax Liability: 2013-2017

Historic Non-Current Deferred Tax Liability for Travere Therapeutics (TVTX) over the last 3 years, with Dec 2017 value amounting to $16.8 million.

  • Travere Therapeutics' Non-Current Deferred Tax Liability fell 65.48% to $16.8 million in Q4 2017 from the same period last year, while for Dec 2017 it was $16.8 million, marking a year-over-year decrease of 65.48%. This contributed to the annual value of $16.8 million for FY2017, which is 65.48% down from last year.
  • According to the latest figures from Q4 2017, Travere Therapeutics' Non-Current Deferred Tax Liability is $16.8 million, which was up 1,317.37% from $1.2 million recorded in Q2 2017.
  • Travere Therapeutics' Non-Current Deferred Tax Liability's 5-year high stood at $48.7 million during Q4 2016, with a 5-year trough of $141,000 in Q4 2014.
  • For the 3-year period, Travere Therapeutics' Non-Current Deferred Tax Liability averaged around $18.8 million, with its median value being $14.6 million (2015).
  • Per our database at Business Quant, Travere Therapeutics' Non-Current Deferred Tax Liability tumbled by 94.58% in 2014 and then soared by 17,153.90% in 2015.
  • Over the past 5 years, Travere Therapeutics' Non-Current Deferred Tax Liability (Quarterly) stood at $2.6 million in 2013, then plummeted by 94.58% to $141,000 in 2014, then surged by 17,153.90% to $24.3 million in 2015, then spiked by 100.18% to $48.7 million in 2016, then crashed by 65.48% to $16.8 million in 2017.
  • Its last three reported values are $16.8 million in Q4 2017, $1.2 million for Q2 2017, and $4.4 million during Q1 2017.